Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

  title={Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.},
  author={Hartmut D{\"o}hner and Elihu H Estey and Sergio Amadori and Frederick R. Appelbaum and Thomas Büchner and Alan K Burnett and Herv{\'e} Dombret and Pierre Fenaux and David Grimwade and Richard A. Larson and Francesco Lo‐Coco and Tomoki Naoe and Dietger Niederwieser and Gert Jan Ossenkoppele and Miguel Angel Sanz and Jorge Sierra and Martin S. Tallman and Bob L{\"o}wenberg and Clara Derber Bloomfield},
  volume={115 3},
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international… 

Figures and Tables from this paper

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Novel approaches to the treatment of acute myeloid leukemia.

  • G. Roboz
  • Medicine
    Hematology. American Society of Hematology. Education Program
  • 2011
The current treatment standards for induction, consolidation, and stem cell transplantation; special considerations in the management of older AML patients; novel agents; emerging data on the detection and management of minimal residual disease (MRD); and strategies to improve the design and implementation of AML clinical trials are described.

Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification

  • Rina Kansal
  • Medicine, Biology
    Cancer biology & medicine
  • 2016
The purpose of this review is to describe some of these recent major advances in the diagnostic classification and risk stratification of AML.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria.

Advances in acute myeloid leukemia

Important updates in diagnostic and disease classifications that reflect new understanding of the biology of AML, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options including cytotoxic chemotherapy, novel targeted agents, and cellular therapies are focused on.

PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG )

It is proposed that the thresholds for diagnosis be reexamined and consensus recommendations are made for diagnosis, as well as, response and progression criteria.

Update on Optimal Management of Acute Myeloid Leukemia

Better efforts to identify those patients who may benefit from more aggressive and investigational therapeutic approaches are needed and newer molecular markers aim at better characterizing the large group of intermediate-risk patients and to identify newer targets for therapy.

Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations

The recommendations for the use of allogeneic transplant given by the literature and by published guidelines are inconsistent and will need clarification.

[Acute leukemia in adults].

Improved standardization and supportive care, particularly due to the introduction of modern antimycotic agents, increase the treatment options and improve the prognosis of patients with acute leukemia.

Impact of genetic targets on cancer therapy in acute myelogenous leukemia.

It remains a great challenge for patients and physicians to consolidate and translate advances in diagnosis, classification, prognosis and ultimately individualized therapy into eventual success in clinic.



Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

  • B. ChesonP. Cassileth M. Keating
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1990
The National Cancer Institute sponsored a workshop to develop a set of standardized diagnostic and response criteria for acute myeloid leukemia (AML) clinical trials, and definitions of response for clinical trials are presented to facilitate comparisons among different studies.

Cytogenetics in acute leukemia.

Current views on clinical relevance of major cytogenetic findings in adult AML and ALL are summarized.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

The classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.

Prognostic index for adult patients with acute myeloid leukemia in first relapse.

The prognostic index estimates the outcome of AML patients in first relapse using four commonly applied clinical parameters and might identify patients who are candidates for salvage and investigational therapy.

Acute myeloid leukemia and acute promyelocytic leukemia.

This work describes the evaluation and management of patients with acute promyelocytic leukemia, a notable example of therapeutic progress in a molecularly defined entity of leukemia, and describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers.

The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.

  • D. Grimwade
  • Biology, Medicine
    Best practice & research. Clinical haematology
  • 2001
There is a rising trend towards routine cytogenetic and molecular characterization of newly diagnosed acute leukaemia, providing a framework for treatment stratification.

Development of minimal residual disease-directed therapy in acute myeloid leukemia.

The challenges involved in extending this concept, to develop a more tailored personalized medicine approach to improve the management and outcome of other forms of AML are considered.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Subgroup analysis demonstrated that the three cytogenetically defined prognostic groups retained their predictive value in the context of secondary as well as de novo AML, within the pediatric age group and furthermore were found to be a key determinant of outcome from autologous or allogeneic bone marrow transplantation (BMT) in first CR.